Clinical Trials
30
Active:1
Completed:20
Trial Phases
3 Phases
Phase 2:13
Phase 3:15
Not Applicable:1
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)β’ Click on a phase to view related trials
Phase 3
15 (51.7%)Phase 2
13 (44.8%)Not Applicable
1 (3.4%)Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
Phase 3
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 2000
- Registration Number
- NCT05157243
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
Phase 3
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 600
- Registration Number
- NCT05157269
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Phase 3
Terminated
- Conditions
- EnterovirusRhinovirus
- Interventions
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 214
- Registration Number
- NCT04489381
- Locations
- πΊπΈ
HealthStar Research LLC, Hot Springs, Arkansas, United States
πΊπΈInvesclinic US LLC, Fort Lauderdale, Florida, United States
πΊπΈRH Medical Urgent Care, Bronx, New York, United States
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Phase 3
Completed
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 935
- Registration Number
- NCT04486313
- Locations
- πΊπΈ
Invesclinic US LLC, Fort Lauderdale, Florida, United States
πΊπΈRH Medical Urgent Care, Bronx, New York, United States
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Phase 3
Completed
- Conditions
- COVID-19Viral Respiratory Illnesses
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 1407
- Registration Number
- NCT04359680
- Locations
- πΊπΈ
HealthStar Research LLC, Hot Springs, Arkansas, United States
πΊπΈSo Cal Clinical Research, Huntington Beach, California, United States
πΊπΈLong Beach Clinical Trials, LLC, Long Beach, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found